Tracheloside

Synopsis

Tracheloside: A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

Tracheloside is a naturally occurring lignan glucoside belonging to the dibenzylbutyrolactone (DBL) class of plant lignans. It carries the CAS registry number 33464-71-0, the molecular formula C₂₇H₃₄O₁₂, and a molecular weight of 550.557 g/mol. It is classified as a lignan-type compound, and high-purity reference standards are typically characterized by HPLC-DAD or HPLC-ELSD analysis, with identity confirmed by mass spectrometry (MS) and nuclear magnetic resonance (NMR). Authoritative databases such as ChEBI (CHEBI:68939) describe it as a natural product found particularly in Carthamus tinctorius and Trachelospermum.

Structurally, tracheloside is the glucoside (glycosylated form) of the aglycone trachelogenin. Tracheloside has an additional hydroxy group at the C-3 position of a tetrahydrofuran moiety compared to the closely related lignan glucoside arctiin. The glucose moiety is attached to an aromatic hydroxyl group, which has direct consequences for the compound's absorption behavior (see Pharmacokinetics, below).

Tracheloside has been identified as a potent α-glucosidase inhibitor and is a natural product found particularly in Carthamus tinctorius (safflower) and Trachelospermum species.

Primary Botanical Sources

Tracheloside is found across several unrelated plant families, giving it an unusually broad botanical distribution among plant lignans:

Trachelospermum jasminoides (Lindl.) Lem. (Confederate jasmine / Star jasmine) — Apocynaceae. This climbing vine is identified as the primary botanical source used in the reference literature, with the species formally listed as Trachelospermum jasminoides (Lindl.) Lem. According to the Chinese Pharmacopoeia, tracheloside is a quality control standard for the genus Trachelospermum plants.
Trachelospermum asiaticum (Siebold & Zucc.) Nakai (Asian jasmine) — Apocynaceae. 138 chemical constituents have been isolated and characterized from these plants, particularly from T. asiaticum and T. jasminoides.
Carthamus tinctorius L. (Safflower) — Asteraceae. The lignan glycoside tracheloside was isolated from seeds of Carthamus tinctorius (Compositae) as an anti-estrogenic principle against cultured Ishikawa cells by employing a bioassay-linked HPLC-ELSD method. The seeds of Carthamus tinctorius contain only small quantities of the active lignan-derivatives, e.g., 3.7–6.6 mg% matairesinol and 14.3–21.7 mg% trachelogenin, but the content of the corresponding glycosides was found to be 5 to 10 times higher.
Leuzea carthamoides (Willd.) DC. (Maral root / Rhaponticum) — Asteraceae. Two lignan glucosides, the known tracheloside and the new carthamoside, together with their two known aglycones, trachelogenin and carthamogenin, were isolated from the seeds of Leuzea carthamoides. Fruit part-specific accumulation studies confirmed that the embryo contains a high amount of lignan glycosides, with tracheloside at 32.9 mg/g and carthamoside at 45.3 mg/g.

Common Forms and Preparations

In research settings, tracheloside is isolated as a pure compound from plant material via solvent extraction, column chromatography on Diaion and silica gel columns, and is characterized to purities of 95–99%+. Tracheloside has been obtained from the seeds of Carthamus tinctorius L. (safflower), with seeds extracted and placed in methanol overnight; the solutions are then concentrated and extracted with hexane, and the methanol-soluble residue is chromatographed on a Diaion column, with fractions containing tracheloside eluted on a silica gel column. In traditional medicine practice, the compound is not administered in isolated form; rather, it is consumed as part of whole-plant preparations—most often as stem decoctions derived from Trachelospermum species, or as seed-based preparations from safflower.

Lignans are the representative and predominant type of compounds from the genus Trachelospermum and are valuable resources for drug design; so far, 33 lignans have been isolated from Trachelospermum plants. In quantitative analytical work, tracheloside is one of five lignans simultaneously determined in the total lignan extract (TLE) from Trachelospermi Caulis, alongside nortracheloside, nortrachelogenin, trachelogenin, and arctigenin, measured at 280 nm by HPLC.

2. Traditional and Historical Use

Traditional Chinese Medicine (TCM)

The dried stems of T. jasminoides — known in Chinese as Luoshiteng (络石藤) — constitute the primary TCM herbal drug source for tracheloside. The dried stem part of T. jasminoides is recorded in various versions of the Chinese Pharmacopoeia and is also used as a herbal medicine in Korea and Japan. In Traditional Chinese Medicine, the dried stem is used alone or mixed with other herbs for the treatment of rheumatism, blood cooling, gonarthritis, backache, pharyngitis, and bruises. The existing literature demonstrates that therapy with this medicine is considered safe and effective both internally and externally.

Plants in the genus Trachelospermum, especially T. jasminoides and T. asiaticum, have a long history of use in China as anti-rheumatic agents and for the treatment of arthritis-related diseases. Notably, the existing literature highlights the need for further gathering of toxicology data, quality-control measures, and clinical value data for the active compounds from genus Trachelospermum, reflecting that formal clinical documentation has historically been sparse.

Korean and Japanese Traditional Medicine

The stems of Trachelospermum plants have been used as local and traditional medicine in China, Japan, and Korea. In Korean traditional medicine, Carthamus tinctorius (safflower, known as Hong Hwa) seeds and flowers have been used alongside the stems of Trachelospermum species. The plant has been used in Korean traditional medicine for maintaining the homeostasis of body circulation.

Persian and Ayurvedic Traditions

While tracheloside as an isolated compound was unknown to historical practitioners, the tracheloside-bearing plant safflower (Carthamus tinctorius) has a deep ethnomedicinal history across South and West Asian medical systems. Safflower is vastly utilized in traditional medicine for various medical conditions, namely dysmenorrhea, amenorrhea, postpartum abdominal pain and mass, and trauma and pain of joints. Based on Persian traditional medicine, safflower has been associated with the treatment of rheumatism and paralysis, vitiligo and black spots, psoriasis, mouth ulcers, phlegm humor, poisoning, numb limbs, and melancholy humor. Seed extracts of Carthamus tinctorius have been traditionally used to treat coronary disease, thrombotic disorders, and menstrual problems, but also against cancer and depression.

Historical Cultivation and Use of Safflower

As early as 4,500 years ago, ancient Egyptians began utilizing safflower for dyeing. From approximately the 4th century B.C. to the 3rd century B.C., safflower was introduced to northwest China from Central Asia. In East Asian countries such as China, Japan, Korea, and Thailand, safflower flowers have been used in traditional Chinese medicine for a long history; safflower flowers are used to treat various diseases, such as cerebrovascular, cardiovascular, and gynecological diseases.

Herbal Combinations and Preparations

Beyond its use as a single herb, tracheloside-containing botanicals have frequently been included in complex herbal combinations. In traditional Chinese and Korean medicine, such plants are often paired with other anti-inflammatory or detoxifying herbs, creating synergistic remedies intended to harmonize bodily functions and promote overall well-being. The most common traditional preparations were aqueous decoctions of the dried stem (Trachelospermi Caulis) and topical applications derived from plant extracts for musculoskeletal pain and inflammation.

3. Key Constituents, Related Compounds, and Mechanisms of Action

Tracheloside and Its Lignan Context

Plants of the genus Trachelospermum are enriched in multiple structurally diverse and biologically important lignans and their glycosides, as well as triterpenoids and flavonoids. Among these compounds, lignans, triterpenoids, and flavonoids are the major bioactive constituents. Tracheloside is the most quantitatively prominent lignan in Trachelospermi Caulis preparations. Quantitative analysis identifies tracheloside as the most abundant compound in the total lignan extract (TLE), alongside nortracheloside, nortrachelogenin, trachelogenin, and arctigenin.

Trachelogenin: The Primary Active Aglycone

Tracheloside functions substantially as a prodrug for its aglycone, trachelogenin, which is generated upon hydrolysis of the glucoside bond. Pharmacokinetic study showed that the glycosidic bond of tracheloside was cleaved in mice stomach and converted to trachelogenin (TCG), indicating TCG as the bioactive compound in vivo. The closely related dibenzylbutyrolactone lignans arctigenin, matairesinol, and trachelogenin exhibit several biological activities, including neuroprotective, anticancer, antihypertensive, antiviral, antioxidant, and anti-inflammatory effects.

Gut Microbial Biotransformation: Enterolactone Pathway

A critical dimension of tracheloside's mechanism of action involves its further transformation by intestinal bacteria into the mammalian lignan enterolactone (ENL), a compound with well-documented phytoestrogenic activity. For the purpose of surveying naturally occurring precursors of oestrogenic substances and their metabolic processes to mammalian lignans such as enterodiol (END) and enterolactone (ENL), trachelogenin — an aglycone of tracheloside occurring in the seeds of Carthamus tinctorius — was demonstrated to transform to seven metabolites, including (−)-ENL, by anaerobic incubation with a human faecal bacterial mixture. The ligand-binding affinity of these metabolites to oestrogen receptors (ERs) α and β was measured; (−)- and (+)-ENL were found to significantly bind to both ERα and ERβ, with an appreciable difference in affinity between (+)- and (−)-ENL for ERβ but not for ERα.

Secoisolariciresinol diglucoside (SDG) and tracheloside (TCL) are the main lignan components of flaxseed cake and safflower seed cake, which are by-products of oil extraction. Both SDG and TCL are metabolized into the mammalian lignan enterolactone (EL) with the involvement of intestinal bacteria.

Anti-Inflammatory Mechanisms

At the molecular level, tracheloside's anti-inflammatory activity in the context of rheumatoid arthritis has been mechanistically characterized. Tracheloside, as the most abundant compound in the total lignan extract from Trachelospermi Caulis, effectively inhibited the release of inflammatory factors IL-6 and IL-17 and suppressed the migration of MH7A cells in vitro. Furthermore, tracheloside reduced the production of key inflammatory factors including COX-2, IL-6, IL-17, MMP2, MMP3, MMP9, JNK, p-JNK, p38, and p-p38 in TNF-α–induced MH7A cells, thereby inhibiting the IL-17/MAPK signaling pathway.

Anti-Estrogenic / Phytoestrogenic Mechanisms

Tracheloside displays context-dependent activity at estrogen-sensitive pathways. Tracheloside was isolated from seeds of Carthamus tinctorius as an anti-estrogenic principle against cultured Ishikawa cells; it significantly decreased the activity of alkaline phosphatase (AP), an estrogen-inducible marker enzyme, with an IC₅₀ value of 0.31 µg/ml, a level of inhibition comparable to that of tamoxifen (IC₅₀ = 0.43 µg/ml). This anti-estrogenic activity — observed in endometrial (Ishikawa) cells — stands in contrast to the phytoestrogenic activity of its downstream gut metabolite enterolactone, illustrating how the compound's net biological effect may depend heavily on the tissue context and individual gut microbiota composition.

Antioxidant and Anticancer Mechanisms

Among the phenolic compounds, tracheloside (TCS) is a major bioactive compound that can combat oxidant stress–related chronic diseases and that also displays anti-tumor activity. In colorectal cancer cell studies, TCS-treated CT26 cells were associated with the upregulation of p16 as well as the downregulation of cyclin D1 and CDK4 in cell cycle arrest. In addition, TCS induced apoptosis of CT26 cells through mitochondria-mediated apoptosis and regulation of the Bcl-2 family. Expression of epithelial–mesenchymal transition (EMT) markers was regulated by TCS treatment in CT26 cells.

Wound Healing / ERK1/2 Pathway

Wound healing activity with tracheloside has been demonstrated to occur through the phosphorylation of ERK1/2 in keratinocyte cell studies.

α-Glucosidase Inhibition

Tracheloside has been characterized as a glucoside compound acting as a potent α-glucosidase inhibitor extracted from safflower seeds. Alpha-glucosidase inhibition is a recognized mechanism for moderating postprandial blood glucose rises, though direct human evidence for tracheloside in this context is currently absent.

4. Scientific Evidence by Area of Use

4.1 Rheumatoid Arthritis and Musculoskeletal Inflammation

This is the area with the most targeted mechanistic study for tracheloside as a discrete compound.

Preclinical / in vitro evidence: Tracheloside, the most abundant compound in the total lignan extract, effectively inhibited the release of inflammatory factors IL-6 and IL-17 and suppressed the migration of MH7A cells (human rheumatoid arthritis fibroblast-like synoviocytes) in vitro. Furthermore, tracheloside reduced the production of key inflammatory factors including COX-2, IL-6, IL-17, MMP2, MMP3, MMP9, JNK, p-JNK, p38, and p-p38 in TNF-α–induced MH7A cells, thereby inhibiting the IL-17/MAPK signaling pathway, and thus contributing to its anti-rheumatoid arthritis effects.

Traditional use corroborated by broader pharmacological review: Modern research has shown that Trachelospermum plants play a role in anti-inflammatory and analgesic effects, antitumor and antiviral effects, although other pharmacology activities have also been documented. Plants in the genus Trachelospermum, especially T. jasminoides and T. asiaticum, have a long history of use in China as anti-rheumatic agents and for the treatment of arthritis-related diseases. In agreement with this traditional usage, several studies have illustrated that plants in this genus possess anti-inflammatory and analgesic effects both in vitro and in vivo.

Evidence strength: Preclinical (cell-based, in vitro). No published human clinical trials specifically evaluating isolated tracheloside for rheumatoid arthritis were identified. In Traditional Chinese Medicine culture, drugs including T. jasminoides stems have been used to cure rheumatism, gonarthritis, backache and pharyngitis, although there are few reports concerning the clinical use and toxicity of these plants. Further attention should be paid to gathering toxicology data, quality-control measures, and the clinical value of the active compounds from genus Trachelospermum.

4.2 Osteoarthritis and Bone Remodeling

Preclinical / in vivo evidence: Research on the closely related aglycone trachelogenin (TCG) — the in vivo form of tracheloside — has been extended to the context of osteoarthritis (OA). Pharmacokinetic study showed that the glycosidic bond of tracheloside was cleaved in mice stomach and converted to trachelogenin (TCG), indicating TCG as the bioactive compound in vivo. A preliminary study unveiled anti-osteoclastogenesis effects of T. jasminoides extract. Considering the vital role of osteoclasts in subchondral bone remodeling during the pathogenesis of OA, a rat OA model induced by joint instability was established to explore the pharmacological effects of TCG in OA prevention.

Bone health via anti-osteoporosis mechanisms: A study evaluated the anti-osteoporosis effects of tracheloside (TCL) and its in vivo metabolites on an alloxan-induced zebrafish model. All the compounds showed significant anti-osteoporosis effects at 80 µM, with p < 0.05 for enterolactone and p < 0.001 for other compounds compared with the model. SDG and TCL showed the most significant and concentration-dependent effects, with p < 0.001 compared with model at 20 µM.

Evidence strength: Preliminary preclinical (zebrafish model, rat model via aglycone TCG). No human clinical trials have been published specifically for tracheloside in osteoporosis or osteoarthritis.

4.3 Colorectal Cancer (Antiproliferative / Anti-metastatic Activity)

In vitro and in vivo preclinical evidence: As confirmed by in vitro and in vivo experiments, tracheloside (TCS) may impede proliferation of and induce apoptosis in CT26 (murine colorectal carcinoma) cells, as it inhibits associated oxidative damage. The anti-tumor effect of TCS might be partially derived from biotransformation occurring through the gut microbiota. A cell viability assay showed that TCS inhibited the proliferation of CRC cells. TCS-treated CT26 cells were associated with the upregulation of p16 as well as the downregulation of cyclin D1 and CDK4 in cell cycle arrest. TCS induced apoptosis of CT26 cells through mitochondria-mediated apoptosis and regulation of the Bcl-2 family. Expression of epithelial–mesenchymal transition (EMT) markers was regulated by TCS treatment in CT26 cells.

Broader antiproliferative evidence: The aglycone trachelogenin was subjected to an antiproliferative study against the SW480 colon adenocarcinoma cell line. In this test, a significant antiproliferative effect of trachelogenin was demonstrated in a concentration range of 22–185 µM.

Evidence strength: Preclinical only (cell lines and animal models). No human clinical trials on tracheloside in cancer have been published. Despite these promising findings, clinical trials in humans are very limited, and more robust research is needed to fully validate the health benefits and safety profile of tracheloside as a nutritional ingredient.

4.4 Anti-Estrogenic Activity and Hormone-Related Conditions

In vitro evidence: Tracheloside was isolated from seeds of Carthamus tinctorius as an anti-estrogenic principle in Ishikawa endometrial cells; it significantly decreased the activity of alkaline phosphatase (AP), an estrogen-inducible marker enzyme, with an IC₅₀ value of 0.31 µg/ml — a level of inhibition comparable to that of tamoxifen (IC₅₀ = 0.43 µg/ml).

Phytoestrogenic activity via gut metabolism: While the parent compound shows anti-estrogenic activity in endometrial cells, its metabolic pathway through gut bacteria leads to the production of the phytoestrogenic mammalian lignan enterolactone. Intervention studies have shown that the ability of the intestinal microbiota of some individuals to convert lignans into enterolignans may result in a reduced risk of hormone-dependent diseases. The transformation of lignans by intestinal microbiota is considered essential in the protection against menopausal symptoms and certain chronic diseases such as cancer, cardiovascular disease, and osteoporosis.

Evidence strength: In vitro cell assay for anti-estrogenic activity. The broader enterolactone/phytoestrogenesis literature is more developed but does not specifically isolate tracheloside's contribution in human subjects. The interplay between direct anti-estrogenic effects and indirect phytoestrogenic effects via gut metabolism is an unresolved area requiring human study.

4.5 Wound Healing and Dermal Keratinocyte Proliferation

In vitro evidence: Tracheloside, which is a plant lignan, has been found to promote the growth of HaCaT cells (human keratinocytes) by over 40% compared to other compounds tested based on a cell proliferation assay. An in vitro scratch assay confirmed the healing activity of tracheloside. Tracheloside promoted the growth of HaCaT cells over 40% compared to other compounds; an in vitro scratch assay confirmed healing activity (more than 2-fold increased healing activity after 24 hours of treatment compared with the control), better than that of allantoin (1.2-fold increased after 24 hours), used as a positive control. With western blot results, wound healing with tracheloside occurred through the phosphorylation of ERK1/2. Therefore, tracheloside is a good candidate to promote wound healing and could be developed as a therapeutic agent for wound treatment or used as a leading compound with higher activity.

Limitation acknowledged by authors: In vivo testing and experiments with epidermal tissue were not performed in this study. These additional data will be needed to show a clearer effect of tracheloside in cell proliferation.

Evidence strength: Preliminary, in vitro only (keratinocyte cell line). No animal or human wound-healing studies on tracheloside have been published.

4.6 Blood Glucose Regulation (Alpha-Glucosidase Inhibition)

Tracheloside has been described as a potent α-glucosidase inhibitor extracted from safflower seeds, and ChEBI identifies it as a natural product found particularly in Carthamus tinctorius and Trachelospermum. This property suggests a potential role in postprandial glycemic management, but no dedicated preclinical or clinical studies specifically examining tracheloside's antidiabetic effect in isolation were identified in peer-reviewed literature at the time of this writing. This area remains speculative pending further investigation.

5. Body Systems and Health Areas of Association

Musculoskeletal system: Anti-inflammatory and analgesic properties relevant to rheumatoid arthritis, osteoarthritis, and connective tissue disorders. Studies have shown that plants from the genus Trachelospermum exhibit an extensive range of pharmacological properties both in vivo and in vitro, including anti-inflammatory, analgesic, antitumor, antiviral and antibacterial activities.
Skeletal system / bone metabolism: Anti-osteoclastogenic effects and potential anti-osteoporotic action, primarily demonstrated via gut-derived enterolactone metabolites and in zebrafish and rat models.
Reproductive endocrine system: Anti-estrogenic activity in endometrial cell models; indirect phytoestrogenic effects via gut microbial conversion to enterolactone.
Gastrointestinal system / gut microbiome: Tracheloside's bioactivity is substantially mediated by gut microbial metabolism; the compound interacts bidirectionally with gut microbiota composition to yield bioactive enterolignans.
Oncology-related pathways: Antiproliferative, pro-apoptotic, and anti-EMT activities demonstrated in colorectal cancer cell lines.
Integumentary system (skin): In vitro keratinocyte proliferation and wound-healing via ERK1/2 phosphorylation.
Carbohydrate metabolism: Inhibitory activity at α-glucosidase, relevant to glycemic regulation.

6. Pharmacokinetics and Metabolism

Gastrointestinal Stability and First-Pass Hydrolysis

Structural transformation studies of arctiin and tracheloside — major components of seeds of Arctium lappa and Carthamus tinctorius, respectively — were investigated using rat gastric juice (pH 1.2–1.5) and rat large intestinal flora in vitro. Both lignans were found to be stable in rat gastric juice. Tracheloside decreased dependently with time in large intestinal flora and was converted to trachelogenin and its major metabolite, 2-(3″,4″-dihydroxybenzyl)-3-(3′,4′-dimethoxybenzyl)-2-hydroxybutyrolactone. These experiments suggest that in the course of lignan metabolism, firstly a cleavage of the glycosidic bond occurred and then demethylation of the phenolic methoxy group in the alimentary tract followed.

Serum Absorption of the Intact Glucoside

The pharmacokinetics of lignan glycosides have not been as extensively studied as for the flavonoids. Arctiin and tracheloside, which are lignan glycosides with the sugar moiety attached to the aromatic hydroxyl group, are hydrolyzed by the intestinal flora of rats, and no intact glucoside has been found in the serum. This indicates that the parent molecule tracheloside is not significantly absorbed intact; systemic activity is primarily mediated by its aglycone trachelogenin and, further downstream, by gut-derived enterolignans.

Conversion to Trachelogenin in Vivo

Preclinical studies in animals indicate that after oral administration, lignans such as arctiin and tracheloside are metabolized to the genins arctigenin and trachelogenin. It was shown that tracheloside can be converted by fecal bacterial mixture of rats to the corresponding aglycone, and might therefore still be bioavailable after oral intake of a safflower preparation. Particularly in the gut, the concentrations of the active compounds can reach high enough concentrations to influence cell metabolism and modulate cytokine profiles in cells of the gastrointestinal tract.

Pharmacokinetic Profiling in Rats

A validated LC/MS-MS method was successfully applied to determine the pharmacokinetic profile of tracheloside and trachelogenin in rat plasma after both oral and intravenous administration of Trachelospermi total lignans. These represent animal pharmacokinetic data only; no human pharmacokinetic studies on isolated tracheloside have been identified in the published literature.

Conversion to Enterolactone: Mammalian Lignan Production

Trachelogenin, the aglycone of tracheloside, was demonstrated to transform to seven metabolites including (−)-enterolactone, by anaerobic incubation with a human faecal bacterial mixture, when the reaction was monitored by LC/MS. This multistep transformation — tracheloside → trachelogenin → enterolactone — places tracheloside within the class of dietary lignan precursors to mammalian phytoestrogens and draws its pharmacological significance into parallel with better-studied lignans such as secoisolariciresinol diglucoside (SDG) from flaxseed.

7. Dosage Forms and Dosages Reported in Studies

No standardized human clinical dosage has been established for tracheloside as an isolated compound. The following dosage information reflects only what has been directly reported in preclinical or analytical research sources:

In vitro anti-estrogenic assay (alkaline phosphatase inhibition, Ishikawa cells): Tracheloside significantly decreased the activity of alkaline phosphatase (AP), an estrogen-inducible marker enzyme, with an IC₅₀ value of 0.31 µg/ml, a level of inhibition comparable to that of tamoxifen (IC₅₀ = 0.43 µg/ml).
In vitro antiproliferative assay (trachelogenin aglycone against SW480 colon adenocarcinoma): Moderate activity of carthamogenin and a significant effect of trachelogenin were demonstrated in a concentration range of 22–185 µM.
Zebrafish anti-osteoporosis model (tracheloside / TCL): All compounds showed significant anti-osteoporosis effects at 80 µM. SDG and TCL showed the most significant and concentration-dependent effects, with p < 0.001 compared with model at 20 µM.
In vitro wound healing (keratinocyte proliferation): Tracheloside promoted the growth of HaCaT cells by over 40% compared to other compounds in a cell proliferation assay, with more than 2-fold increased healing activity after 24 hours of treatment compared with the control in a scratch assay.
Content in plant material (Leuzea carthamoides embryo fraction): The embryo of Leuzea carthamoides fruit contains a high amount of lignan glycosides: tracheloside at 32.9 mg/g and carthamoside at 45.3 mg/g.
Content in safflower seeds: The seeds of Carthamus tinctorius contain only small quantities of the active lignan aglycone trachelogenin (14.3–21.7 mg%), but the content of the corresponding glycoside (tracheloside) was found to be 5 to 10 times higher.

8. Safety Considerations and Notable Interactions

Absence of Formal Human Toxicology Data

In Traditional Chinese Medicine culture, drugs that include T. jasminoides stems have been used to cure rheumatism, gonarthritis, backache, and pharyngitis, although there are few reports concerning the clinical use and toxicity of these plants. Further attention should be paid to gathering information about their toxicology data, quality-control measures, and the clinical value of the active compounds from genus Trachelospermum. No formal human toxicology studies on isolated tracheloside appear in the peer-reviewed literature at the time of this writing. Formal safety parameters such as a no-observed-adverse-effect level (NOAEL) or lethal dose (LD₅₀) in humans have not been established for the isolated compound.

Anti-Estrogenic Activity: Potential Relevance for Hormone-Sensitive Conditions

Tracheloside was identified as an anti-estrogenic principle against cultured Ishikawa endometrial cells, with inhibitory potency comparable to tamoxifen at the concentrations tested. This in vitro finding suggests that individuals with hormone-sensitive conditions (e.g., hormone-receptor-positive breast cancer, endometriosis) or those taking estrogenic medications or hormonal therapies should be aware of this potential, though in vivo relevance in humans remains uncharacterized. The compound's net estrogenic/anti-estrogenic effect in vivo will likely depend significantly on individual gut microbiota composition, which determines the extent of conversion to the phytoestrogenic metabolite enterolactone.

Gut Microbiota Dependency

Although epidemiological and experimental evidence indicates that the intake of phytoestrogens in foods may protect against certain chronic diseases, discrepancies between the in vivo and in vitro assays with phytoestrogens have been observed. These discrepancies could be explained by the low bioavailability of phytoestrogens. Because tracheloside is not absorbed as the intact glucoside but rather metabolized by intestinal bacteria, the biological effects of tracheloside-containing preparations are expected to vary substantially between individuals depending on gut microbiome composition and the presence or absence of specific lignan-metabolizing bacterial strains.

Traditional Safety Record of Parent Plants

The existing literature on T. jasminoides demonstrates that therapy with this medicine is considered safe and effective both internally and externally, based on the historical record of use in TCM. However, this general safety record applies to the whole-plant preparation and cannot be directly extrapolated to high-dose, isolated tracheloside supplementation.

Overall Evidentiary Status

Clinical trials in humans are very limited, and more robust research is needed to fully validate the health benefits and safety profile of tracheloside as a nutritional ingredient. The compound's scientific investigation remains almost entirely at the preclinical stage — in vitro cell studies and small animal models. Establishing validated safety and efficacy profiles in humans will require dedicated pharmacokinetic, toxicological, and randomized controlled trial research.